| 2933.19.18 | 00 | 2-Chloro-5-sulfophenylmethylpyrazolone; 2,5-Dichloro-4-(3-methyl-5-oxo-2- pyrazolin-1-yl) benzenesulfonic acid; Phenylcarbethoxypyrazolone; m-Sulfaminopyrazolone (m-Sulfamido- phenylmethylpyrazolone); and 1-(p-Sulfophenyl)-3-methylpyrazolone | kg | Free | | 15.4¡é/kg + 52% |
| 2933.21.00 | 00 | Compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.29.05 | 00 | 1-[1-((4-Chloro-2-(trifluoromethyl)phenyl)- imino)-2-propoxyethyl]-1H-imidazole (Triflumizole); and Ethylene thiourea | kg | Free | | 15.4¡é/kg + 52% |
| 2933.29.10 | 00 | 2-Phenylimidazole | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,MA,MX, P,SG) | 15.4¡é/kg + 39.5% |
| 2933.31.00 | 00 | Compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.33.00 | 00 | Alfentanil (INN), anileridine (INN), bezitramide (INN), bromazepam (INN), difenoxin (INN), diphenoxylate (INN), dipipanone (INN), fentanyl (INN), ketobemidone (INN), methylphenidate (INN), pentazocine (INN), pethidine (INN), pethidine (INN) intermediate A, phencyclidine (INN) (PCP), phenoperidine (INN), pipradrol (INN), piritramide (INN), propiram (INN) and trimeperidine (INN); salts thereof | kg | Free | | 15.4¡é/kg + 149.5% |
| 2933.39.08 | 00 | 1-(3-Sulfopropyl)pyridinium hydroxide; N,N'-Bis(2,2,6,6-tetramethyl-4-piperidinyl)-1,6- hexanediamine; 3,5-Dimethyl-2-hydroxymethyl-4-methoxy- pyridine (pyrmethyl alcohol); Dipentamethylenethiuram tetrasulfide; 2H-Indol-2-one,1,3-dihydro-1-phenyl-3-(4- pyridinylmethylene); 4-Picolyl chloride hydrochloride; and Piperidinoethyl chloride hydrochloride | kg | Free | | 15.4¡é/kg + 52% |
| 2933.39.20 | 00 | p-Chloro-2-benzylpyridine; 4-Chloro-1-methylpiperidine hydrochloride; 1,4-Dimethyl-6-hydroxy-3-cyanopyrid-2-one; Di-(2,2,6,6-tetramethyl-4-hydroxy- piperidine)sebacate; 2-Methyl-5-ethylpyridine; 4-Phenylpropylpyridine; α-Phenylpyridylacetic acid, methyl ester; Picolinic acid; 2-Pyridinecarboxaldehyde; and 2,5-Pyridinedicarboxylic acid | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¡é/kg + 39.5% |
| 2933.39.31 | 00 | Antidepressants, tranquilizers and other psychotherapeutic agents | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 3.1% (SG) | 15.4¡é/kg + 149.5% |
| 2933.39.61 | 10 | 3-Quinuclidinyl benzilate | kg | | | |
| 2933.41.00 | 00 | Compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused: | | | | |
| 2933.52 | | Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: | | | | |
| 2933.53.00 | 00 | Allobarbital (INN), amobarbital (INN), barbital (INN), butalbital (INN), butobarbital, cyclobarbital (INN), methylphenobarbital (INN), pentobarbital (INN), phenobarbital (INN), secbutabarbital (INN), secobarbital (INN) and vinylbital (INN); salts thereof | kg | Free | | 50% |
| 2933.59.22 | 00 | Anti-infective agents: | | | | |
| 2933.59.46 | 00 | Antidepressants, tranquilizers and other psychotherapeutic agents | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 3.1% (SG) | 15.4¡é/kg + 149.5% |
| 2933.61.00 | 00 | Compounds containing an unfused triazine ring (whether or not hydrogenated) in the structure: | | | | |
| 2933.69.20 | 00 | 2,4-Diamino-6-phenyl-1,3,5-triazine | kg | Free | | 25% |
| 2933.79.04 | 00 | 2,5-Dihydro-3,6-diphenylpyrrolo-(3,4-c)- pyrrole-1,4-dione | kg | Free | | 15.4¡é/kg + 52% |
| 2933.99.01 | 00 | Butyl (R)-2-[4-(5-trifluoromethyl-2- pyridinyloxy)phenoxy]propanoate | kg | Free | | 15.4¡é/kg + 50% |
| 2933.99.02 | 00 | 2-[4-[(6-Chloro-2-quinoxalinyl)oxy]phenoxy]- propionic acid, ethyl ester; and O,O-Dimethyl-S-[(4-oxo-1,2,3-benzotri- azin-3-(4H)-yl)methyl]phosphorodithioate | kg | Free | | 15.4¡é/kg + 64.5% |
| 2933.99.06 | 00 | α-Butyl- α-(4-chlorophenyl)-1H-1,2,4- triazole-1- propanenitrile (Myclobutanil); and α-[2-(4-Chlorophenyl)ethyl]- α-phenyl-1H- 1,2,4-triazole-1-propanenitrile (Fenbuconazole) | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4¡é/kg + 64.5% |
| 2933.99.08 | 00 | Acetoacetyl-5-aminobenzimidazolone; 3-(2H-Benzotriazol-2-yl)-5-(tert-butyl)-4- hydroxybenzene propanoic acid, C7-C9 branched or linear alkyl esters; 2-(2H-Benzotriazol-2-yl)-6-dodecyl-4- methyl phenol, in liquid form, branched and linear; and 1,3,3-Trimethyl-2-methyleneindoline | kg | Free | | 15.4¡é/kg + 52% |
| 2933.99.12 | 00 | 6-Bromo-5-methyl-1H-imidazo[4,5-b]- pyridine; 2-sec-Butyl-4-tert-butyl-6-(benzotriazol-2- yl)phenol; 2-tert-Butyl-4-methyl-6-(5-chlorobenzotri- azol-2-yl)phenol; 2,4-Di-tert-butyl-6-(benzotriazol-2-yl)phenol; 2,4-Di-tert-butyl-6-(5-chlorobenzotriazol-2- yl)phenol; 2,3-Dichloro-6-quinoxalinecarbonyl chloride; 1-Hydroxy-2-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid; 2-Hydroxy-3-carbazolecarboxylic acid, sodium salt; Iminodibenzyl(10,11-dihydro-5H-dibenz- [b,f]azepine); Indoline; 3-Methylbenzo[f]quinoline; 2-Methylindoline; 2-Methylmercaptobenzimidazole; 1-Methyl-2-phenylindole; 1-Methylpyrazine; 2,4-Methylpyrazolic acid; 2-Phenylbenzimidazole; 2-Phenylindole; Tetramethylpyrazine; 2,3,5-Triphenyltetrazolium chloride; dl-Tryptophan; and Vinylcarbazole, monomer | kg | 5.8% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P,SG) | 15.4¡é/kg + 39.5% |
| 2933.99.14 | 00 | 5-Amino-4-chloro- α-phenyl-3- pyridazinone | kg | 6.5% | Free (A,AU,BH,CA, CL,E,IL,J,JO, MA,MX, P,SG) | 15.4¡é/kg + 40.5% |
| 2933.99.16 | 00 | o-Diquat dibromide (1,1'-Ethylene- 2,2'-dipyridylium dibromide) | kg | Free | | 15.4¡é/kg + 40.5% |
